Table 4.
Comparative association of the variant rs3812718 in Sodium Voltage-Gated Channel Alpha Subunit 1 (SCN1A) gene and susceptibility to temporal lobe epilepsy and Online Archive of Brazilian Mutations (ABraOM, from Portuguese Arquivo Brasileiro On-line de Mutações) controls.
| Genotypes and Alleles | Patients n (%) a | Controls n (%) b | p-Value (p-Corrected) | OR (95%CI) |
|---|---|---|---|---|
| GG | 30 (25.00) | 245 (20.90) | 0.144 * (1.000) | 1.54 (0.90–2.62) |
| GA | 60 (50.00) | 549 (46.90) | 0.211 * (1.000) | 1.37 (0.87–2.17) |
| AA | 30 (25.00) | 377 (32.20) | Reference | |
| GG + AA | 60 (50.00) | 622 (53.10) | Reference | |
| GA | 60 (50.00) | 549 (46.90) | 0.579 * (1.000) | 1.13 (0.78–1.65) |
| GG + GA | 90 (75.00) | 794 (67.80) | Reference | |
| AA | 30 (25.00) | 377 (32.20) | 0.131 * (1.000) | 0.70 (0.46–1.08) |
| GA + AA | 90 (75.00) | 926 (79.00) | Reference | |
| GG | 30 (25.00) | 245 (21.00) | 0.357 * (1.000) | 1.26 (0.81–1.95) |
| Allele A | 120 (50.00) | 1303 (50.66) | Reference | |
| Allele G | 120 (50.00) | 1269 (49.34) | 0.898 * (1.000) | 1.03 (0.79–1.34) |
| Genotypes and Alleles | Drug-Resistant n (%) c | Controls n (%) | p-Value (p-Corrected) | OR (95%CI) |
| GG | 17 (26.15) | 245 (20.90) | 0.090 * (1.000) | 2.01 (0.96–4.22) |
| GA | 35 (53.85) | 549 (46.90) | 0.084 * (1.000) | 1.85 (0.97–3.54) |
| AA | 13 (20.00) | 377 (32.20) | Reference | |
| GG + AA | 30 (46.15) | 622 (53.10) | Reference | |
| GA | 35 (53.85) | 549 (46.90) | 0.334 * (1.000) | 1.32 (0.80–2.18) |
| GG + GA | 52 (80.00) | 794 (67.80) | Reference | |
| AA | 13 (20.00) | 377 (32.20) | 0.055 * (1.000) | 0.53 (0.28–0.98) |
| GA + AA | 48 (73.85) | 926 (79.00) | Reference | |
| GG | 17 (26.15) | 245 (21.00) | 0.396 * (1.000) | 1.34 (0.76–2.37) |
| Allele A | 61 (46.90) | 1303 (50.66) | Reference | |
| Allele G | 69 (53.10) | 1269 (49.34) | 0.458 * (1.000) | 1.16 (0.82–1.65) |
| Genotypes and Alleles | Drug-Responsive n (%) d | Controls n (%) | p-Value (p-Corrected) | OR (95%CI) |
| GG | 13 (23.64) | 245 (20.90) | 0.810 * (1.000) | 1.18 (0.56–2.47) |
| GA | 25 (45.45) | 549 (46.90) | 0.897 * (1.000) | 1.01 (0.54–1.90) |
| AA | 17 (30.91) | 377 (32.20) | Reference | |
| GG +AA | 30 (54.55) | 622 (53.10) | Reference | |
| GA | 25 (45.45) | 549 (46.90) | 0.945 * (1.000) | 0.94 (0.55–1.63) |
| GG + GA | 38 (69.09) | 794 (67.80) | Reference | |
| AA | 17 (30.91) | 377 (32.20) | 0.959 * (1.000) | 0.94 (0.53–1.69) |
| GA + AA | 42 (76.36) | 926 (79.00) | Reference | |
| GG | 13 (23.64) | 245 (21.00) | 0.754 * (1.000) | 1.17 (0.62–2.21) |
| Allele A | 59 (53.60) | 1303 (50.66) | Reference | |
| Allele G | 51 (46.40) | 1269 (49.34) | 0.607 * (1.000) | 0.89 (0.60–1.30) |
| Genotypes and Alleles | Drug-Resistant n (%) c | Drug-Responsive n (%) d | p-Value (p-Corrected) | OR (95%CI) |
| GG | 17 (26.15) | 13 (23.64) | 0.439 * (1.000) | 1.71 (0.62–4.76) |
| GA | 35 (53.85) | 25 (45.45) | 0.264 * (1.000) | 1.83 (0.76–4.44) |
| AA | 13 (20.00) | 17 (30.91) | Reference | |
| GG + AA | 30 (46.15) | 30 (54.55) | Reference | |
| GA | 35 (53.85) | 25 (45.45) | 0.464 * (1.000) | 1.40 (0.68–2.89) |
| GG + GA | 52 (80.00) | 38 (69.09) | Reference | |
| AA | 13 (20.00) | 17 (30.91) | 0.245 * (1.000) | 0.56 (0.24–1.29) |
| GA + AA | 48 (73.85) | 42 (76.36) | Reference | |
| GG | 17 (26.15) | 13 (23.64) | 0.916 * (1.000) | 1.14 (0.41–2.63) |
| Allele A | 61 (46.90) | 59 (53.60) | Reference | |
| Allele G | 69 (53.10) | 51 (46.40) | 0.365 * (1.000) | 1.31 (0.79–2.18) |
*, Chi-square with Yates correction; %, percentage; 95%CI, 95% confidence interval; n, number of individuals; OR, odds ratio: (a) 1.000; (b) 0.228; (c) 0.808; (d) 0.816. Values below 0.05 indicate that the sample is out of Hardy–Weinberg equilibrium. An alpha error of 0.05 was adopted in the statistical analysis. p-corrected was adjusted using Bonferroni correction for multiple comparisons.